Neil Pugach
Chesapeake, VANPI 1689675258
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $207,935 of the $244,204 with a category attached, or 85.1%. 15 manufacturers reported payments, led by Lilly USA, LLC at 29.5% of the total. Reporting peaked in 2020 at $71,392 and has fallen 70.3% since, to $21,192 in 2025.
Across 670 payments — averaging $364.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$72K
- AbbVie$67K
- Amgen$52K
- Teva Pharmaceuticals USA, Inc.$27K
- Pfizer$15K
- Biohaven Pharmaceuticals, Inc.$5K
- plus $6K from 9 others
What the payments were for
- Consulting fees$8,3483%
- Speaking & faculty fees$207,93585%
- Grants$440%
- Travel & lodging$18,2197%
- Food & beverage$9,1654%
- Education$4940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 103 | $72,129 |
| AbbVie(2 entities) | 268 | $67,126 |
| Amgen | 110 | $52,484 |
| Teva Pharmaceuticals USA, Inc. | 44 | $26,706 |
| Pfizer | 44 | $15,082 |
| Biohaven Pharmaceuticals, Inc. | 18 | $4,550 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $3,276 |
| Lundbeck LLC | 22 | $2,162 |
| Novartis | 22 | $296 |
| Currax Pharmaceuticals LLC | 9 | $121 |
| Impel Pharmaceuticals LLC | 4 | $78 |
| Upsher-smith Laboratories LLC | 4 | $71 |
| Amneal Pharmaceuticals LLC | 5 | $67 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Bausch Health US, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 38 | $67,266 |
| Nurtec OdtRimegepant Sulfate | 34 | $30,111 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $12,058 |
| Ondansetron Hcl | 19 | $1,844 |
| Butorphanol Tartrate | 42 | $1,679 |
| Topiramate | 40 | $914 |
| Zolmitriptan OdtZolmitriptan | 12 | $792 |
| RizatriptanRizatriptan Benzoate | 27 | $758 |
| Levetiracetam | 13 | $547 |
| Memantine Hcl | 16 | $440 |
| Naratriptan Hcl | 13 | $360 |
| Pregabalin | 17 | $360 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $213 |
| Sumatriptan Succinate | 31 | $185 |
| Sertraline Hcl | 19 | $171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $67,126 | $67,26638 claims |
| PfizerNurtec Odt | $15,082 | $30,11134 claims |
| Upsher-smith Laboratories LLCTopiramate | $71 | $91440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Virginiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.